CDEK
← All drugs Report issue

ivabradine

Trade name: corlanor

Small moleculeapprovedFast Track FDA

Approved

Apr 15, 2015

Ivabradine (CORLANOR®) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker that reduces the spontaneous pacemaker activity of the cardiac sinus node by selectively inhibiting the If-current, resulting in heart rate reduction at concentrations that do not affect other cardiac ionic currents. Specific heart-rate lowering with ivabradine (CORLANOR®) reduces myocardial oxygen demand, simultaneously improving oxygen supply. It has no negative inotropic or lusitropic effects, preserving ventricular contractility, and does not change any major electrophysiological parameters unrelated to heart rate. — NCATS

Clinical trial activity

84 trials · 91 clinical orgs · 8 marketing orgs

Phase 1
3
Phase 2
32
Phase 3
21
Phase 4
33

Earliest trial started Sep 1, 2004 (NCT00202579)

Timeline

2000s

  1. Jan 1, 2004

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 3 Sponsor(trial)

  3. Jan 1, 2007

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Apr 15, 2015

    Amgen — Earliest FDA Approval

  2. Apr 15, 2015

    Amgen — NDA Organization

2020s

  1. Dec 30, 2021

    Ingenus Pharmaceuticals — Marketing Organization

  2. Dec 30, 2021

    Centaur Pharmaceuticals — Marketing Organization

  3. Apr 19, 2022

    Alembic — Marketing Organization

  4. Oct 5, 2022

    Annora Pharma — Marketing Organization

  5. Nov 29, 2023

    Zydus Discovery DMCC — Marketing Organization

  6. Sep 5, 2024

    Bionpharma Inc — Marketing Organization

  7. Apr 28, 2025

    MSN Laboratories — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewFast trackApr 15, 2015

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2
Mol. weight
468.59 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Prescription Only

Oral

Yes

Parenteral

No

Topical

No

First in class

Sources

Also known as

  • 3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one
  • 3-[3-({[(7s)-3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl}(methyl)amino)propyl]-7,8-dimethoxy-2,3,4,5-tetrahydro-1h-3-benzazepin-2-one
  • 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2h-benzazepin-2-one
  • amg-998
  • amg-998
  • coraxan
  • corlanor
  • corlanor
  • corlanor
  • corlanor
  • corlanor
  • corlanor
  • corlanor
  • corlanor
  • corlentor
  • ivabradin
  • ivabradin
  • ivabradina
  • ivabradina
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine
  • ivabradine hcl
  • ivabradine hydrochloride
  • ivabradine hydrochloride
  • ivabradine hydrochloride
  • ivabradine hydrochloride
  • ivabradine hydrochloride
  • ivabradinum
  • ivabradinum
  • procoralan
  • procoralan
  • procoralan
  • s 16257
  • s-16257
  • s-16257
  • s-16257
  • s 16257-2
  • s-16257-2
  • s 16260-2
  • s-16260-2

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07268170Phase 2/Phase 3 (Phase 3)Dec 15, 2025Gødstrup Hospital
NCT07135258Phase 4Oct 1, 2025The University of Hong Kong
NCT06742164N/ADec 30, 2024Ain Shams University
NCT06305806Phase 2Mar 11, 2024Duke University, Harvard University, Johns Hopkins University, University of California, San Diego, Vanderbilt University
NCT06305780Phase 2Mar 11, 2024Duke University, Harvard University, Johns Hopkins University, University of California, San Diego, Vanderbilt University
NCT06670690N/ASep 1, 2023Menoufia University
NCT05882708Phase 4Jun 1, 2023Guangzhou Medical University
NCT06371222Phase 4Feb 1, 2023Bangladesh Medical University
NCT05481177Phase 4Nov 15, 2022Uniformed Services University of the Health Sciences
NCT05594342Phase 3Jul 1, 2022The Young Investigator Group of Cardiovascular Research
NCT05279651Phase 3Jun 13, 2022Jagiellonian University, McMaster University, Vanderbilt University
NCT05141071Phase 2Nov 25, 2021Cairo University
NCT05348057Phase 4Aug 1, 2021People's Liberation Army of China
NCT04853797N/AApr 16, 2021University of Copenhagen
NCT05261464Phase 4Jan 30, 2021Mahidol University
NCT04580342Phase 2Oct 15, 2020Assiut University
NCT04436016Phase 4Sep 30, 2020University of Geneva
NCT04448899Phase 4Jun 1, 2020Alexandria University, Damanhour University
NCT04405804Phase 2May 31, 2020Bambino Gesù Hospital and Research Institute, Government of Italy
NCT04186286Phase 2Dec 15, 2019Dysautonomia International, University of Calgary
Showing 20 of 84 trials
Page 1 / 5

Organizations

Research & Development (91)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AmgenFor profit7232016
ServierFor profit7532004
Ain Shams UniversityAcademic/Hospital3322018
Duke UniversityAcademic/Hospital3322016
Harvard UniversityAcademic/Hospital3112017
University of California, San DiegoAcademic/Hospital3122017
University of Campania Luigi VanvitelliAcademic/Hospital3312010
Vanderbilt UniversityAcademic/Hospital3022022
Alexandria UniversityAcademic/Hospital2122019
Cairo UniversityAcademic/Hospital2222014
Johns Hopkins UniversityAcademic/Hospital2012024
Monash UniversityAcademic/Hospital2212008
Policlinico CasilinoAcademic/Hospital2222013
University of CopenhagenAcademic/Hospital2222018
University of LeedsAcademic/Hospital2212013
University of Sao PauloAcademic/Hospital2222013
Vita-Salute University of Milano. ItalyAcademic/Hospital2122009
American Heart AssociationAcademic/Hospital1012016
Assistance Publique - Hôpitaux de ParisAcademic/Hospital1112019
Assiut UniversityAcademic/Hospital1112020
91 organizations
Page 1 / 5

Marketing (9)

OrganizationOrg typeRelationshipDate
AlembicFor profitMKTGApr 19, 2022
AlembicFor profitSYNNov 8, 2024
AmgenFor profitNDAApr 15, 2015
Annora PharmaFor profitMKTGOct 5, 2022
Bionpharma IncFor profitMKTGSep 5, 2024
Centaur PharmaceuticalsFor profitMKTGDec 30, 2021
Ingenus PharmaceuticalsFor profitMKTGDec 30, 2021
MSN LaboratoriesFor profitMKTGApr 28, 2025
Zydus Discovery DMCCFor profitMKTGNov 29, 2023